Thyroid cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• ERK 0
• MEK 1
• PSMA 1
• RAS 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• CTNNB1 0
• KRAS 1
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• HMGB1 0
• IDH 0
• IDO1 0
• NLRP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 33+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  HEC169096 in Participants With Advanced Solid Tumors

  NCT05451602· Sunshine Lake Pharma Co., Ltd.· Updated 14 Oct 2026

  “Sponsor strategic decision; the study will not continue.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

  NCT04760288· Hoffmann-La Roche· Updated 5 Jan 2024

  “Due to several logistical challenges during start-up which could not be overcome study was withdrawn.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Natural History Study of Children and Adults With Medullary Thyroid Cancer

  NCT01660984· National Cancer Institute (NCI)· Source

• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

  NCT07822880· Eli Lilly and Company· Source

• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

  NCT04280081· Eli Lilly and Company· Source

• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

  NCT04211337· Loxo Oncology, Inc.· Source

• A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

  NCT04760288· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

See which targets of this disease your abstract mentions, and go to the people working on them.